Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29081910 | 1.00 | HDAC6 (0.35) | HDAC6HTTNPC1GAAMAPK1 | |
| SCHEMBL30470780 | 1.00 | HDAC6 (0.35) | HDAC6HTTNPC1GAAMAPK1 | |
| SCHEMBL24367600 | 0.89 | HDAC6 (0.32) | HDAC6NPC1GAAMAPK1RAB9A | |
| SCHEMBL32689101 | 0.89 | HDAC6 (0.32) | HDAC6NPC1GAAMAPK1RAB9A | |
| SCHEMBL24366026 | 0.89 | HDAC6 (0.32) | HDAC6NPC1GAAMAPK1RAB9A | |
| SCHEMBL30471172 | 0.89 | HDAC6 (0.32) | HDAC6NPC1GAAMAPK1RAB9A | |
| SCHEMBL24364706 | 0.87 | HDAC6 (0.33) | HDAC6 | |
| SCHEMBL29081812 | 0.87 | HDAC6 (0.33) | HDAC6 | |
| SCHEMBL30470714 | 0.87 | HDAC6 (0.33) | HDAC6 | |
| SCHEMBL32689015 | 0.85 | HDAC6 (0.41) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | HDAC6 299/4885HTT 616/4885NPC1 39/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | HDAC6 299/4885HTT 616/4885NPC1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.